Answers are grounded in this paper and cite their sources.
Background: Predictive performance is necessary but insufficient for G protein-coupled receptor (GPCR) ligand prioritization, where heterogeneous bioactivity data, analog-series overlap, receptor-state dependence, and polypharmacology can weaken high-scoring predictions. Methods: We developed an auditable ligand- and structure-based workflow across five human GPCRs: DRD2, CB2, ADORA2A, OPRM1, and CCR5. ChEMBL Ki, IC50, and EC50 data were evaluated using scaffold-disjoint validation, external validation, Venn–Abers calibration, conformal prediction, applicability-domain analysis, explainability, and receptor-state-aware docking. Results: Deployed classifiers achieved held-out ROC-AUC values of 0.876–0.929. Under stricter temporal validation, models developed exclusively on pre-cutoff data achieved ROC-AUC values of 0.617–0.894 on the same post-cutoff scaffold-held-out compounds, indicating optimism in the original temporal stress test arising from post-cutoff analog information. De-overlapped BindingDB validation was informative for ADORA2A (n = 134) and OPRM1 (n = 49), whereas smaller DRD2, CB2, and CCR5 strata were descriptive only. Venn–Abers provided validity-aware probability intervals, although calibration metrics did not improve uniformly. Classification error increased outside the applicability domain for all targets, while regression conformal coverage decreased. Morgan fingerprints dominated predictive discrimination, whereas physicochemical descriptors recurred more frequently among top SHAP features across targets. DrugBank screening yielded 92 high-confidence, dataset-novel predictions, with structure-based filtering reducing prioritization to three evidence-classified compounds across three targets. Conclusions: Overall, the study presents a reliability-aware framework for evidence-qualified GPCR ligand prioritization rather than an experimentally confirmed candidate-discovery campaign. Prospective biochemical and functional validation, including potency and selectivity assessment where appropriate, is required before candidate-level conclusions can be established.
No takes yet. Share an insight, caveat, or question.
Mtambo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: